Research programme: small glycanic drugs - Endotis
Alternative Names: EP 30; EP 31; EP 32; EP 33; EP 80061; EP8000; Small glycanic drugs research programme - EndotisLatest Information Update: 03 Oct 2015
At a glance
- Originator Endotis Pharma
- Class Oligosaccharides
- Mechanism of Action Chemokine receptor antagonists; Intercellular signalling peptide and protein inhibitors; Interferon gamma inhibitors; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 02 Mar 2011 Preclinical development in Solid tumours is ongoing in France
- 01 Jan 2011 Preclinical trials in Cancer in France (Parenteral)
- 17 Apr 2010 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)